OMEGA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.35 USD | +0.86% |
|
-2.89% | -21.93% |
| Apr. 16 | Omega Therapeutics CFO Joshua Reed to Depart | MT |
| Apr. 16 | Omega Therapeutics, Inc. Announces Executive Changes, Effective as of May 31, 2024 | CI |
Financials (USD)
| Sales 2024 * | 3.37M | Sales 2025 * | 800K | Capitalization | 129M |
|---|---|---|---|---|---|
| Net income 2024 * | -74M | Net income 2025 * | -91M | EV / Sales 2024 * | 31.4 x |
| Net cash position 2024 * | 22.77M | Net cash position 2025 * | 150M | EV / Sales 2025 * | -26.3 x |
| P/E ratio 2024 * |
-1.89
x | P/E ratio 2025 * |
-1.88
x | Employees | 94 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on Omega Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.86% | ||
| 1 week | -2.89% | ||
| Current month | -35.62% | ||
| 1 month | -31.09% | ||
| 3 months | -38.48% | ||
| 6 months | +42.42% | ||
| Current year | -21.93% |
1 week
2.20
2.54
1 month
2.203.77
Current year
2.206.30
1 year
1.3010.09
3 years
1.3031.41
5 years
1.3031.41
10 years
1.3031.41
| Managers | Title | Age | Since |
|---|---|---|---|
Mahesh Karande
CEO | Chief Executive Officer | 51 | 19-05-31 |
Joshua Reed
DFI | Director of Finance/CFO | 51 | 22-05-22 |
| Chief Tech/Sci/R&D Officer | - | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Luke Beshar
BRD | Director/Board Member | 65 | 21-04-30 |
John Mendlein
BRD | Director/Board Member | 64 | 19-12-31 |
Christian Schade
CHM | Chairman | 63 | 23-07-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +1.75% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 2.35 | +0.86% | 250 228 |
| 24-04-24 | 2.33 | -0.43% | 200,139 |
| 24-04-23 | 2.34 | -2.09% | 301,577 |
| 24-04-22 | 2.39 | -0.42% | 193,038 |
| 24-04-19 | 2.4 | -0.83% | 401,872 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Companyâs OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Companyâs precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.33
USD
Average target price
11
USD
Spread / Average Target
+372.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.93% | 129M | |
| +1.12% | 43.84B | |
| +6.77% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.01% | 25.53B | |
| -24.92% | 18.18B | |
| -3.63% | 12.29B | |
| +27.16% | 12.29B | |
| +7.30% | 11.15B |
- Stock Market
- Equities
- OMGA Stock
